biomedcentral.com/bmcmed/article
Bottom,Top,Right1
  • Log on
  •   BioMed Central
  • Journals
  • Gateways
BMC Medicine
official impact factor 6.04
Search for
Advanced search
  • Home
  • Articles
  • Authors
  • Reviewers
  • About this journal
  • My BMC Medicine

Submit a manuscript Register Sign up for article alerts Contact us Follow us on Twitter

Explore BMC Medicine

  •  Editorial Board
  •  Instructions for authors
  •  FAQ
Advertisement

Articles

  • All articles
  • Most popular RSS
  • Archive
  • Article collections

Volume 2 (2004) - October 2004

next >
up
< previous

Research article   Open Access Highly Accessed

Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: A systematic review and meta-analysis

Sean M Bagshaw, William A Ghali BMC Medicine 2004, 2:38 (22 October 2004)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central |  Editor’s summary

A systematic review shows that the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy on patients undergoing angiography remains unclear and highlights the need for a large, multi-center trial.

Research article   Open Access Highly Accessed

Significance of MDR1 and multiple drug resistance in refractory human epileptic brain

Nicola Marchi, Kerri L Hallene, Kelly M Kight, Luca Cucullo, Gabriel Moddel, William Bingaman, Gabriele Dini, Annamaria Vezzani, Damir Janigro BMC Medicine 2004, 2:37 (9 October 2004)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central |  Editor’s summary

The overexpression of multiple drug resistance protein (MDR1) in cells from the brains of epileptics who are refractory to drug treatment may result in lower penetrance of drugs into active sites and also be associated with higher neuroglial survival and reduced apoptosis.


  • Terms and Conditions
  • Privacy statement
  • Press
  • Information for advertisers
  • Jobs at BMC
  • Support
  • Contact us

© 2013 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.